Related Experiment Videos
Clinical research on antiangiogenic therapy
R A Kuiper1, J H Schellens, G H Blijham
1Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands.
Abstract:
A promising novel target for anti-cancer therapy is the tumour vasculature. Both primary tumour growth and the formation of metastasis depend on the establishment of new blood vessels from preexisting ones, a process called angiogenesis. Inhibition of angiogenesis and targeting of the tumour vasculature are highly effective in controlling tumour growth. Several natural and synthetic compounds have been developed and are currently tested in pre-clinical and clinical studies. This review intends to provide an overview of agents with antiangiogenic activity and the early clinical experience with these drugs.
Insights
Targeting tumor blood vessels, or angiogenesis, is a key anti-cancer strategy. This review covers agents that inhibit angiogenesis and their early clinical results in cancer therapy.
Area of Science:
- Oncology
- Vascular Biology
Background:
- Tumor vasculature is a critical target for anti-cancer therapies.
- Tumor growth and metastasis rely on angiogenesis (new blood vessel formation).
- Inhibiting angiogenesis effectively controls tumor progression.
Purpose of the Study:
- To review agents with anti-angiogenic activity.
- To summarize early clinical experiences with these anti-angiogenic drugs.
Main Methods:
- Literature review of anti-angiogenic agents.
- Analysis of pre-clinical and clinical study data.
Main Results:
- Several natural and synthetic compounds show anti-angiogenic potential.
- Early clinical studies are evaluating these agents for cancer treatment.
Conclusions:
- Targeting tumor vasculature via angiogenesis inhibition is a promising anti-cancer approach.
- Further clinical evaluation of anti-angiogenic agents is ongoing.